Long-term Documentation of the Utilization of Otezla® in Patients With Plaque Psoriasis Under Routine Conditions (LAPIS-Pso)

Change from baseline in the Dermatology Life Quality Index (DLQI) ≤ 5 or improvement in DLQI by ≥ 5 points at Visit 2 from baseline

Change from Baseline in the Dermatology Life Quality Index (DLQI) ≤ 5 or improvement in DLQI by ≥ 5 points at all other visits from baseline.

Change in the Physician Global Assessment (PGA) Score

Percent Change in Percent of Affected Body Surface Area (BSA)

Percent Change in the Psoriasis Area Severity Index (PASI) Score

Change in the Patient's Global Assessment (PaGA)

Patient Preference Questionnaire (PPQ)

Patient Satisfaction (Systemic Therapy Adherence Questionnaire, STAQ)

Change in Pain (Visual Analogue Scale; VAS)

Adverse Events (AEs)

Change in Itch (Pruritus) (Visual Analogue Scale; VAS)

Change in Scalp Involvement -Physician's Global Assessment (PGA)

Change in Scalp Involvement - Patient's Global Assessment (PaGA)

Change in Nail Involvement - Target Nail Psoriasis Severity Index (NAPSI)

Change in Nail Involvement Fingernail - Patient's Global Assessment (PaGA)

Change in Palmoplantar involvement - Palmoplantar physician's global assessment (PGA)

Change in Palmoplantar involvement - Palmoplantar patient's global assessment (PaGA)